RT Journal Article
SR Electronic
T1 Endothelial dysfunction in patients with chronic obstructive pulmonary disease and concomitant arterial hypertension and its correction by telmisartan plus amlodipine fixed combination
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP PA4617
DO 10.1183/13993003.congress-2016.PA4617
VO 48
IS suppl 60
A1 Bolieva, Laura
YR 2016
UL https://publications.ersnet.org//content/48/suppl_60/PA4617.abstract
AB Background. The concomitant prevalence of arterial hypertension (AH) and chronic obstructive pulmonary disease (COPD) is very high. Endothelial dysfunction (ED) seems to be the most common pathogenetic mechanism of both COPD and AH, so study of additional pleiotropic effects of antihypertensive drugs seems to be actual.Aims. The study was carried out to evaluate the ability of telmisartan (T) plus amlodipin (A) fixed combination to correct ED in patients with COPD and AH.Methods. Patients with COPD and AH (n=142) received T 40 mg/A 5 mg (T/A) for AH treatment for 12 weeks. ED markers (endothelin-1 (E-1), sP-selectin, ICAM-1, IL-1β, homocysteine (H)) blood levels were assessed by enzyme-linked immunosorbent assay at baseline and after 3 months of treatment. All data analyses were performed using Statistica for Windows, Release 10.0 StatSoft, Inc.Results. E-1, sP-selectin, ICAM-1, IL-1β, H levels were significantly higher in patients with COPD and AH vs normal values at baseline. The decrease in the levels of all tested markers was shown after 12 weeks of treatment comparing with baseline: E-1 level decreased by 51.6%, sP-selectin by 28.4%, ICAM-1 by 34.3%, IL-1β by 50.8% and H by 58.8% (p <0.001).Conclusions. The results of the study show that treatment of the patients with COPD and AH with T/A provides significant reduction of ED markers. This confirms the presence of pleiotropic effects of T/A and good prospects of its use for management of AH in patients with COPD.